COVIDRIVE expands its scope of studies, becoming id.DRIVE

id.DRIVE is a public-private-partnership consisting of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in Europe. This work is the result of funding toward a research network of hospitals provided by several pharmaceutical companies. id.DRIVE leverages the COVID-19 vaccine effectiveness (VE) platform, COVIDRIVE ( (2021-2023) and the Influenza VE platform, DRIVE ( (2017-2022).

Now, the partnership has decided to make use of the established consortium and study network to expend its scope to all infectious diseases (IDs), lending its name to the new partnership id.Drive. Alongside vaccines, other pharmaceutical products such as antivirals and monoclonal antibodies will be studied. While id.DRIVE will continue performing COVID-19 effectiveness studies, the consortium will initiate a first surveillance study starting mid-2024 on many other respiratory pathogens such as Influenza, RSV, Adenovirus, Human enterovirus, Parainfluenza virus, etc. This surveillance will help to understand the impact of these respiratory pathogens on serious illness, and to monitor the effectiveness of pharmaceutical products that are already available or will be available to prevent and cure these viral illnesses. 

The id.DRIVE public-private partnership includes 8 partners, with AstraZeneca, Janssen, GSK, Novavax, Valneva and Pfizer as pharmaceutical company partners, P95 a small and medium enterprise (SME) and Fisabio, a Spanish regional public health institute.  The id.DRIVE study network covers 13 European countries and comprises 32 Study contributors, 5 primary care networks, and a nation-wide register.

id.DRIVE is open for new partners to join the partnership and is expanding its study network. To join us as an id.DRIVE partner or study site, contact us at 

Find out more at